Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grisham

Showing results (811-820 of 834) with videos related to

Pageof 84
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian CancerRachel N Grisham, Brooke E Sylvester, Helen Won, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
Med (New York, N.Y.)|November 11, 2023
Transforming ovarian cancer care by targeting minimal residual diseaseAmir A Jazaeri, Rachel Grisham, Anne Knisely, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2026
A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent Copy-Number High/p53-Abnormal Endometrial CancerMaria M Rubinstein, Jennifer Y Ge, Qin Zhou, et al.
Gynecologic Oncology|May 7, 2023
Germline drivers of gynecologic carcinosarcomasTiffany Y Sia, Sushmita B Gordhandas, Ozge Birsoy, et al.
Gynecologic Oncology|January 24, 2020
Low-grade serous ovarian cancer: State of the scienceBrian Slomovitz, Charlie Gourley, Mark S Carey, et al.
Biology of Sex Differences|February 21, 2026
Sry-modified laboratory rat lines to study sex-chromosome effects underlying sex differences in physiology and disease: four core genotypes and moreArthur P Arnold, Xuqi Chen, Michael N Grzybowski, et al.
Gynecologic Oncology|December 2, 2023
Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survivalRyan M Kahn, Pier Selenica, Thomas Boerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian CancerRachel N Grisham, Ignace Vergote, Susana Banerjee, et al.
Nature Medicine|April 23, 2024
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analysesClaire F Friedman, Beryl L Manning-Geist, Qin Zhou, et al.
Pageof 84

Showing results (811-820 of 834) with videos related to

Sort By:
Pageof 84
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian CancerRachel N Grisham, Brooke E Sylvester, Helen Won, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
Med (New York, N.Y.)|November 11, 2023
Transforming ovarian cancer care by targeting minimal residual diseaseAmir A Jazaeri, Rachel Grisham, Anne Knisely, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2026
A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent Copy-Number High/p53-Abnormal Endometrial CancerMaria M Rubinstein, Jennifer Y Ge, Qin Zhou, et al.
Gynecologic Oncology|May 7, 2023
Germline drivers of gynecologic carcinosarcomasTiffany Y Sia, Sushmita B Gordhandas, Ozge Birsoy, et al.
Gynecologic Oncology|January 24, 2020
Low-grade serous ovarian cancer: State of the scienceBrian Slomovitz, Charlie Gourley, Mark S Carey, et al.
Biology of Sex Differences|February 21, 2026
Sry-modified laboratory rat lines to study sex-chromosome effects underlying sex differences in physiology and disease: four core genotypes and moreArthur P Arnold, Xuqi Chen, Michael N Grzybowski, et al.
Gynecologic Oncology|December 2, 2023
Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survivalRyan M Kahn, Pier Selenica, Thomas Boerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian CancerRachel N Grisham, Ignace Vergote, Susana Banerjee, et al.
Nature Medicine|April 23, 2024
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analysesClaire F Friedman, Beryl L Manning-Geist, Qin Zhou, et al.
Pageof 84